Ontology highlight
ABSTRACT:
SUBMITTER: Kaplan JB
PROVIDER: S-EPMC4739416 | biostudies-literature | 2016 Jan
REPOSITORIES: biostudies-literature
Kaplan Jason B JB Stein Brady L BL McMahon Brandon B Giles Francis J FJ Platanias Leonidas C LC
EBioMedicine 20160113
Despite the emergence of JAK inhibitors, there is a need for disease-modifying treatments for Philadelphia-negative myeloproliferative neoplasms (MPNs). JAK inhibitors ameliorate symptoms and address splenomegaly, but because of the heterogeneous contributors to the disease process, JAK inhibitor monotherapy incompletely addresses the burden of disease. The ever-growing understanding of MPN pathogenesis has provided the rationale for testing novel and targeted therapeutic agents, as monotherapie ...[more]